欧洲专利局授予IRLAB对帕金森病药物mesdopetam的专利,将市场独占权延长到2040年代中期. The EPO granted IRLAB a patent for mesdopetam, a Parkinson’s drug, extending market exclusivity into the mid-2040s.

欧洲专利局计划授予IRLAB治疗技术公司一项新专利,用于治疗帕金森病症状的药物候选者Mesdopetam,涵盖该化合物的多种盐形式。 The European Patent Office plans to grant IRLAB Therapeutics a new patent for mesdopetam, a drug candidate for treating Parkinson’s disease symptoms, covering multiple salt forms of the compound. 这一补充加强了IRLAB的知识产权,支持未来的商业化,并将市场独家权延长到2040年代中期. This addition strengthens IRLAB’s intellectual property, supporting future commercialization and extending market exclusivity into the mid-2040s. 该专利是在美国、中国和日本事先批准之后获得的。 The patent follows prior approvals in the U.S., China, and Japan. 瑞典生物技术公司IRLAB(IRLAB)正利用其系统生物学平台推进Parkinson的多项治疗, IRLAB, a Swedish biotech firm, is advancing several Parkinson’s treatments using its systems biology platform and is listed on Nasdaq Stockholm.